Cargando…

Impact of radiologic splenic vessel invasion in resectable left-sided pancreatic ductal adenocarcinoma: predictor of early systemic recurrence following upfront surgery

BACKGROUND: The aim of this study is to identify prognostic factors and the best candidates for neoadjuvant therapy among patients with resectable left-sided pancreatic ductal adenocarcinoma (PDAC) by analyzing the timing and pattern of recurrence following upfront surgery. METHODS: This single-cent...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Seung Jae, Hwang, Dae Wook, Lee, Jae Hoon, Song, Ki Byung, Lee, Woohyung, Park, Yejong, Kim, Song Cheol
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9638787/
https://www.ncbi.nlm.nih.gov/pubmed/36353584
http://dx.doi.org/10.21037/gs-22-304
_version_ 1784825501865476096
author Lee, Seung Jae
Hwang, Dae Wook
Lee, Jae Hoon
Song, Ki Byung
Lee, Woohyung
Park, Yejong
Kim, Song Cheol
author_facet Lee, Seung Jae
Hwang, Dae Wook
Lee, Jae Hoon
Song, Ki Byung
Lee, Woohyung
Park, Yejong
Kim, Song Cheol
author_sort Lee, Seung Jae
collection PubMed
description BACKGROUND: The aim of this study is to identify prognostic factors and the best candidates for neoadjuvant therapy among patients with resectable left-sided pancreatic ductal adenocarcinoma (PDAC) by analyzing the timing and pattern of recurrence following upfront surgery. METHODS: This single-center retrospective study included patients with resectable left-sided PDAC who underwent upfront distal pancreatectomy from 2005 to 2015. A minimum P value approach was used to evaluate the optimal cutoff of early recurrence. The predictors of recurrence were assessed with Cox regression analysis. RESULTS: Among 311 included patients, 241 (77.5%) had a recurrence at a median follow-up of 29.3 months. Systemic recurrence occurred in 194 patients (80.5%) and isolated local recurrence in 47 patients (19.5%). A recurrence-free survival cutoff of 12 months was selected to distinguish between early and late recurrence. The patients with early recurrence had a shorter median overall survival (16.1 vs. 39.9 months, P<0.001) and post-recurrence survival (9.6 vs. 17.2 months, P<0.001) than those with late recurrence. The patients with systemic recurrence had a shorter median overall survival (19.6 vs. 29.1 months, P=0.007) and post-recurrence survival (11.0 vs. 15.3 months, P=0.024) than those with an isolated local recurrence. In multivariable analysis, preoperative CA 19-9 ≥500 U/mL [odd ratio (OR) 2.037, P=0.035], radiologic splenic vessels invasion (OR 5.014, P<0.001), positive radial resection margin (OR 2.638, P<0.001), and no adjuvant chemotherapy (OR 2.084, P=0.001) were predictors of an early systemic recurrence. CONCLUSIONS: Radiologic splenic vessels invasion may be considered to indicate a biologically borderline status in patients with anatomically resectable left-sided PDAC. Future clinical trials of neoadjuvant therapy targeting these patients should be conducted.
format Online
Article
Text
id pubmed-9638787
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-96387872022-11-08 Impact of radiologic splenic vessel invasion in resectable left-sided pancreatic ductal adenocarcinoma: predictor of early systemic recurrence following upfront surgery Lee, Seung Jae Hwang, Dae Wook Lee, Jae Hoon Song, Ki Byung Lee, Woohyung Park, Yejong Kim, Song Cheol Gland Surg Original Article BACKGROUND: The aim of this study is to identify prognostic factors and the best candidates for neoadjuvant therapy among patients with resectable left-sided pancreatic ductal adenocarcinoma (PDAC) by analyzing the timing and pattern of recurrence following upfront surgery. METHODS: This single-center retrospective study included patients with resectable left-sided PDAC who underwent upfront distal pancreatectomy from 2005 to 2015. A minimum P value approach was used to evaluate the optimal cutoff of early recurrence. The predictors of recurrence were assessed with Cox regression analysis. RESULTS: Among 311 included patients, 241 (77.5%) had a recurrence at a median follow-up of 29.3 months. Systemic recurrence occurred in 194 patients (80.5%) and isolated local recurrence in 47 patients (19.5%). A recurrence-free survival cutoff of 12 months was selected to distinguish between early and late recurrence. The patients with early recurrence had a shorter median overall survival (16.1 vs. 39.9 months, P<0.001) and post-recurrence survival (9.6 vs. 17.2 months, P<0.001) than those with late recurrence. The patients with systemic recurrence had a shorter median overall survival (19.6 vs. 29.1 months, P=0.007) and post-recurrence survival (11.0 vs. 15.3 months, P=0.024) than those with an isolated local recurrence. In multivariable analysis, preoperative CA 19-9 ≥500 U/mL [odd ratio (OR) 2.037, P=0.035], radiologic splenic vessels invasion (OR 5.014, P<0.001), positive radial resection margin (OR 2.638, P<0.001), and no adjuvant chemotherapy (OR 2.084, P=0.001) were predictors of an early systemic recurrence. CONCLUSIONS: Radiologic splenic vessels invasion may be considered to indicate a biologically borderline status in patients with anatomically resectable left-sided PDAC. Future clinical trials of neoadjuvant therapy targeting these patients should be conducted. AME Publishing Company 2022-10 /pmc/articles/PMC9638787/ /pubmed/36353584 http://dx.doi.org/10.21037/gs-22-304 Text en 2022 Gland Surgery. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Original Article
Lee, Seung Jae
Hwang, Dae Wook
Lee, Jae Hoon
Song, Ki Byung
Lee, Woohyung
Park, Yejong
Kim, Song Cheol
Impact of radiologic splenic vessel invasion in resectable left-sided pancreatic ductal adenocarcinoma: predictor of early systemic recurrence following upfront surgery
title Impact of radiologic splenic vessel invasion in resectable left-sided pancreatic ductal adenocarcinoma: predictor of early systemic recurrence following upfront surgery
title_full Impact of radiologic splenic vessel invasion in resectable left-sided pancreatic ductal adenocarcinoma: predictor of early systemic recurrence following upfront surgery
title_fullStr Impact of radiologic splenic vessel invasion in resectable left-sided pancreatic ductal adenocarcinoma: predictor of early systemic recurrence following upfront surgery
title_full_unstemmed Impact of radiologic splenic vessel invasion in resectable left-sided pancreatic ductal adenocarcinoma: predictor of early systemic recurrence following upfront surgery
title_short Impact of radiologic splenic vessel invasion in resectable left-sided pancreatic ductal adenocarcinoma: predictor of early systemic recurrence following upfront surgery
title_sort impact of radiologic splenic vessel invasion in resectable left-sided pancreatic ductal adenocarcinoma: predictor of early systemic recurrence following upfront surgery
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9638787/
https://www.ncbi.nlm.nih.gov/pubmed/36353584
http://dx.doi.org/10.21037/gs-22-304
work_keys_str_mv AT leeseungjae impactofradiologicsplenicvesselinvasioninresectableleftsidedpancreaticductaladenocarcinomapredictorofearlysystemicrecurrencefollowingupfrontsurgery
AT hwangdaewook impactofradiologicsplenicvesselinvasioninresectableleftsidedpancreaticductaladenocarcinomapredictorofearlysystemicrecurrencefollowingupfrontsurgery
AT leejaehoon impactofradiologicsplenicvesselinvasioninresectableleftsidedpancreaticductaladenocarcinomapredictorofearlysystemicrecurrencefollowingupfrontsurgery
AT songkibyung impactofradiologicsplenicvesselinvasioninresectableleftsidedpancreaticductaladenocarcinomapredictorofearlysystemicrecurrencefollowingupfrontsurgery
AT leewoohyung impactofradiologicsplenicvesselinvasioninresectableleftsidedpancreaticductaladenocarcinomapredictorofearlysystemicrecurrencefollowingupfrontsurgery
AT parkyejong impactofradiologicsplenicvesselinvasioninresectableleftsidedpancreaticductaladenocarcinomapredictorofearlysystemicrecurrencefollowingupfrontsurgery
AT kimsongcheol impactofradiologicsplenicvesselinvasioninresectableleftsidedpancreaticductaladenocarcinomapredictorofearlysystemicrecurrencefollowingupfrontsurgery